The Kallikrein-related peptidase, KLK4, has been shown to be significantly overexpressed in prostate tumours in numerous studies and is suggested to be a potential biomarker for prostate cancer.
KLK4 may also play a role in prostate cancer progression through its involvement in epithelial-mesenchymal transition, a more aggressive phenotype, and metastases to bone. It is well known that genetic variation has the potential to affect gene expression and/or various protein characteristics and hence we sought to investigate the possible role of single nucleotide polymorphisms (SNPs) in the KLK4 gene in prostate cancer. Assessment of 61 SNPs in the KLK4 locus (± 10 kb) in approximately 1300 prostate cancer cases and 1300 male controls for associations with prostate cancer risk and/or prostate tumour aggressiveness (Gleason score < 7 versus ≥ 7) revealed 7 SNPs to be associated with a decreased risk of prostate cancer at the Ptrend< 0.05 significance level. Three of these SNPs, rs268923, rs56112930 and the HapMap tagSNP rs7248321, are located several kb upstream of KLK4; rs1654551 encodes a non-synonymous serine to alanine substitution at position 22 of the long isoform of the KLK4 protein, and the remaining 3 risk-associated SNPs, rs1701927, rs1090649 and rs806019, are located downstream of KLK4 and are in high linkage disequilibrium with each other (r2 ≥ 0.98). Our findings provide suggestive evidence of a role for genetic variation in the KLK4 locus in prostate cancer predisposition.
Written by:
Lose F, Srinivasan S, O'Mara T, Marquart L, Chambers S, Gardiner RA, Aitken JF; Australian Prostate Cancer BioResource, Spurdle AB, Batra J, Clements JA. Are you the author?
Molecular Cancer Epidemiology Group, Genetics and Population Health Division, Queensland Institute of Medical Research, 300 Herston Rd, Herston, Brisbane, Queensland, Australia.
Reference: PLoS One. 2012;7(9):e44520.
doi: 10.1371/journal.pone.0044520
PubMed Abstract
PMID: 22970239
UroToday.com Investigative Urology Section
